Patients
62 % of married women 15–49
Contraception use, Spain, 2018 (World Bank).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Europe Contraceptive Innovations Market Industry Trends and Forecast to 2034: Segmented by (Product, Hormone, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$446.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $856.3 Mn | — | — |
| 2025 (base) | $895.6 Mn | +$39.4 Mn | — |
| 2026 (forecast) | $936.8 Mn | +$41.2 Mn | +4.6% |
| 2027 (forecast) | $979.9 Mn | +$43.1 Mn | +9.4% |
| 2028 (forecast) | $1.03 Bn | +$45.1 Mn | +14.4% |
| 2029 (forecast) | $1.07 Bn | +$47.2 Mn | +19.7% |
| 2030 (forecast) | $1.12 Bn | +$49.3 Mn | +25.2% |
| 2031 (forecast) | $1.17 Bn | +$51.6 Mn | +31% |
| 2032 (forecast) | $1.23 Bn | +$54.0 Mn | +37% |
| 2033 (forecast) | $1.28 Bn | +$56.4 Mn | +43.3% |
| 2034 (forecast) | $1.34 Bn | +$59.0 Mn | +49.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $895.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.34 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, hormone and end user (see all) |
| Key players | Bayer AG, Organon, Perrigo Company plc, Evofem Biosciences, Mithra Pharmaceuticals and 1 more (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Contraceptive innovations are newer birth-control options such as hormone-free gels, long-acting injectables, vaginal rings and over-the-counter pills.
Key segments of the contraceptive Innovations market include product (Over-the-Counter Pills, Long-Acting Injectables and Vaginal Rings) and hormone (Hormonal and Non-Hormonal).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the contraceptive Innovations market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the contraceptive Innovations market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the contraceptive Innovations market.
The contraceptive Innovations market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for contraceptive Innovations. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in Contraceptive Innovations right now, from free public sources.
62 % of married women 15–49
Contraception use, Spain, 2018 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 16 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe
Europe
Europe
Europe
Healthcare Services · Europe
Medical Devices · Europe
Healthcare Services · Europe
Digital Health · Europe
Healthcare Services · Europe
Healthcare Services · Europe